Dopamine D3 receptor antagonists: a patent review (2007 – 2012)

Bibliography

• Sokoloff P, Giros B, Martres M-P, Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Dias J, Le Foll B, The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:25-43
   PubMedGoogle Scholar
• Micheli F, Heidbreder C. Selective dopamine D3 receptor antagonists; 1997 – 2007: a decade of progress. Expert Opin Ther Patents 2008;18:821-40
   Web of Science ®Google Scholar
• Micheli F. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective. ChemMedChem 2011;6:1152-62
   PubMed Web of Science ®Google Scholar
• Hackling AE, Stark H. Dopamine D3 receptor ligands with antagonist properties. ChemBioChem 2002;3:946-61
   PubMed Web of Science ®Google Scholar
• Heidler P, Zohrabi-Kalantari V, Calmels T, Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides. Bioorg Med Chem 2005;13:2009-14
   PubMedGoogle Scholar
• Reavill C, Taylor SG, Wood MD, Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. Pharmacol Exp Ther 2000;294:1154-65
   PubMed Web of Science ®Google Scholar
• Pryde DC, Dalvie D, Hu Q, Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 2010;53:8441-60
   PubMed Web of Science ®Google Scholar
• Newman AH, Blaylock BL, Nader MA, Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 2012;84(7):882-90. Available from: http://dx.doi.org/10.1016/j.bcp.2012.06.023
   PubMed Web of Science ®Google Scholar
• Bonanomi G, Di Fabio R, Fazzolari E, Glaxo Group Ltd. WO2007022933; 2007
   Google Scholar
• Capelli AM, Fazzolari E, Micheli F, Glaxo Group Ltd. WO2007022936; 2007
   Google Scholar
• Gentile G, Hamprecht D, Micheli F, Glaxo Group Ltd. WO2007022935; 2007
   Google Scholar
• Arista L, Checchia A, Gentile G, Glaxo Group Ltd. WO2007022934; 2007
   Google Scholar
• Bertani B, Micheli F, Pasquarello A, Glaxo Group Ltd. WO2007113258; 2007
   Google Scholar
• Bertani B, Bonanomi G, Capelli AM, Glaxo Group Ltd. WO2007113232; 2007
   Google Scholar
• Bertani B, Checchia A, Di Fabio R, Glaxo Group Ltd. WO2007113260; 2007
   Google Scholar
• Bertani B, Cardullo F, Dambruoso P, Glaxo Group Ltd. WO2009043883; 2009
   Google Scholar
• Bertani B, Cremonesi S, Fontana S, Glaxo Group Ltd. WO2009043884; 2009
   Google Scholar
• Bertani B, Di Fabio R, Micheli F, Glaxo Group Ltd. WO2007125061; 2007
   Google Scholar
• Anderton CL, Bacchi S, Beato S, Glaxo Group Ltd. WO2008022994; 2008
   Google Scholar
• Hamprecht D, Heidbreder C, Melotto S, Glaxo Group Ltd. WO2007022980; 2007
   Google Scholar
• Grandel R, Braje WM, Haupt A, Abbott GmbH & Co. KG, Germany. WO2007118859; 2007
   Google Scholar
• Braje W, Turner SC, Haupt A, Abbott GmbH & Co. KG, Germany. WO2009056625; 2009
   Google Scholar
• Turner SC, Haupt A, Braje W, Abbott GmbH & Co. KG, Germany. WO2009056600; 2009
   Google Scholar
• Grandel R, Braje WM, Haupt A, Abbott GmbH & Co. KG, Germany. WO2007118900; 2007
   Google Scholar
• Grandel R, Braje WM, Haupt A, Abbott GmbH & Co. KG, Germany. WO2007118899; 2007
   Google Scholar
• Gobbi L, Jaeschke G, Rodriguez Sarmiento RM, F. Hoffmann-La Roche AG, Switz. US20100075979; 2010
   Google Scholar
• Gobbi L, Jaeschke G, Rodriguez Sarmiento RM, F. Hoffmann-La Roche AG, Switz. US20100075981; 2010
   Google Scholar
• Prior KJ, Jaeschke G, Sarmiento RM, F. Hoffmann-La Roche AG, Switz. US20100075985; 2010
   Google Scholar
• Gobbi L, Jaeschke G, Luebbers T, F. Hoffmann-La Roche AG, Switz. WO2007093540; 2007
   Google Scholar
• Gobbi L, Jaeschke G, Luebbers T, F. Hoffmann-La Roche AG, Switz. US20080103174; 2008
   Google Scholar
• Gobbi L, Jaeschke G, Luebbers T, F. Hoffmann-La Roche AG, Switz. WO2009013212; 2009
   Google Scholar
• Gobbi L, Jaeschke G, Luebbers T, F. Hoffmann-La Roche AG, Switz. WO2009019174; 2009
   Google Scholar
• Gobbi L, Jaeschke G, Luebbers T, F. Hoffmann-La Roche AG, Switz. WO2010031735; 2010
   Google Scholar
• Gobbi L, Sarmiento RM, Wichmann J, F. Hoffmann-La Roche AG, Switz. US20110313151; 2011
   Google Scholar
• Gobbi L, Sarmiento RM, Wichmann J, F. Hoffmann-La Roche AG, Switz. WO2012004206; 2012
   Google Scholar
• Sarmiento RM, Wichmann J; F. Hoffmann-La Roche AG, Switz. WO2012080149; 2012
   Google Scholar
• Wager TT, Chandrasekaran RY, Butler TW; Pfizer Products, Inc. WO2008026046; 2008
   Google Scholar
• Capet M, Danvy D, Levoin N, Bioprojet Fr. WO2007148208; 2007
   Google Scholar
• Sokoloff P, Imbert T, Vergnes L, Pierre Fabre Medicament, Fr. WO2008009741; 2008
   Google Scholar
• Sokoloff P, Imbert T, Leriche L, Pierre Fabre Medicament, Fr. WO2011027289; 2011
   Google Scholar
• Sokoloff P, Imbert T, Leriche L, Pierre Fabre Medicament, Fr. Demande. FR2949465; 2011
   Google Scholar
• De Nanteuil G, Cimetiere B, Dekeyne A, Les Laboratoires Servier, Fr. WO2011010014; 2011
   Google Scholar
• Newman AH, Grundt P, Cyriac GC, The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA. WO2008153573; 2008
   Google Scholar
• Li J, Yang R, Song R, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China, Peop. Rep. China. WO2010040274; 2010
   Google Scholar
• Wang S, Chen J, Collins G, University of Michigan, USA. WO2010025235; 2010
   Google Scholar
• Campiani G, Butini S, Fattorusso C, Universita degli Studi di Siena, Italy. WO2008043839; 2008
   Google Scholar
• Peters D, Roenn LC, Nielsen KS, NeuroSearch A/S, Den. WO2009095438; 2009
   Google Scholar
• Peters D, Roenn LC, Nielsen KS, NeuroSearch A/S, Den. WO2009112568; 2011
   Google Scholar
• Peters D, Roenn LC, Nielsen KS; NeuroSearch A/S, Den. WO2010040808; 2010
   Google Scholar
• Barta Szalai G, Agai Csongor E, Domany G, Richter Gedeon Nyrt, Hung. WO2008125891; 2008
   Google Scholar
• Barta Szalai G, Agai Csongor E, Domany G, Richter Gedeon Nyrt, Hung. US20090143398; 2009
   Google Scholar
• Newman AH, Beuming T, Banala AK, Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem 2012;55:6689-99
   PubMed Web of Science ®Google Scholar
• Diaz J, Pilon C, Le Foll B, Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000;20:8677-84
   PubMed Web of Science ®Google Scholar
• Gehlert DR. Quantitative autoradiography of Gpp(NH)p sensitive and insensitive [3H]quinpirole binding sites in the rat brain. Synapse 1993;14:113-20
   PubMedGoogle Scholar
• Stanwood GD, Artymyshyn RP, Kung MP, Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 2000;295:1223-31
   PubMedGoogle Scholar
• Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 1998;800:269-74
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60-80
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer B, Mengod G, Palacios JM. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 1993;18:187-92
   PubMedGoogle Scholar
• Hall H, Halldin C, Dijkstra D, Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berl) 1996;128:240-7
   PubMedGoogle Scholar
• Herroelen L, De Backer JP, Wilczak N, Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 1994;648:222-8
   PubMedGoogle Scholar
• Murray AM, Ryoo HL, Gurevich E, Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994;91:11271-5
   PubMed Web of Science ®Google Scholar
• von Economo C, Koskinas GN. The cytoarchitectonics of the human cerebral cortex. Oxford University Press, London; 1929
   Google Scholar
• Nimchinsky EA, Vogt BA, Morrison JH, Spindle neurons of the human anterior cingulate cortex. J Comp Neurol 1995;355:27-37
   PubMed Web of Science ®Google Scholar
• Nimchinsky EA, Gilissen E, Allman JM, A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci USA 1999;96:5268-73
   PubMed Web of Science ®Google Scholar
• Butti C, Santos M, Uppal N, Von Economo neurons: clinical and evolutionary perspectives. Cortex 2011; Epub ahead of print
   PubMedGoogle Scholar
• Allman JM, Tetreault NA, Hakeem AY, The von Economo neurons in the frontoinsular and anterior cingulate cortex. Ann NY Acad Sci 2011;1225:59-71
   PubMed Web of Science ®Google Scholar
• Allman JM, Tetreault NA, Hakeem AY, The von Economo neurons in apes and humans. Am J Hum Biol 2011;23:5-21
   PubMedGoogle Scholar
• Berthoz S, Armony JL, Blair RJ, An fMRI study of intentional and unintentional (embarrassing) violations of social norms. Brain 2002;125:1696-708
   PubMed Web of Science ®Google Scholar
• Spence SA, Hunter MD, Farrow TF, A cognitive neurobiological account of deception: evidence from functional neuroimaging. Philos Trans R Soc Lond B Biol Sci 2004;359:1755-62
   PubMed Web of Science ®Google Scholar
• Naqvi NH, Rudrauf D, Damasio H, Damage to the insula disrupts addiction to cigarette smoking. Science 2007;315:531-4
   PubMed Web of Science ®Google Scholar
• Mash DC. D3 receptor binding in human brain during cocaine overdose. Mol Psychiatry 1997;2:5-6
   PubMedGoogle Scholar
• Mash DC, Staley JK. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 1999;877:507-22
   PubMed Web of Science ®Google Scholar
• Segal DM, Moraes CT, Mash DC. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997;45:335-9
   PubMedGoogle Scholar
• Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996;16:6100-6
   PubMed Web of Science ®Google Scholar
• Le Foll B, Frances H, Diaz J, Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002;15:2016-26
   PubMed Web of Science ®Google Scholar
• Neisewander JL, Fuchs RA, Tran-Nguyen LT, Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004;29:1479-87
   PubMed Web of Science ®Google Scholar
• Le Foll B, Diaz J, Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003;47:176-83
   PubMed Web of Science ®Google Scholar
• Le Foll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol Psychiatry 2003;8:225-30
   PubMed Web of Science ®Google Scholar
• Spangler R, Goddard NL, Avena NM, Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain Res Mol Brain Res 2003;111:74-83
   PubMedGoogle Scholar
• Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J 2006;20:2223-33
   PubMed Web of Science ®Google Scholar
• Boileau I, Payer D, Houle S, Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 2012;32:1353-9
   PubMed Web of Science ®Google Scholar
• Wilson AA, McCormick P, Kapur S, Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005;48:4153-60
   PubMedGoogle Scholar
• Gallezot JD, Beaver JD, Gunn RN, Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012;66:489-500
   PubMedGoogle Scholar
• Ginovart N, Willeit M, Rusjan P, Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-71
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A, Willeit M, Ginovart N, Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 2008;29:400-10
   PubMedGoogle Scholar
• Kiss B, Horti F, Bobok A. In vitro and in vivo comparison of [3H](+)-PHNO and [3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D3 from D2 receptor sites. Synapse 2011;65:467-78
   PubMedGoogle Scholar
• Narendran R, Slifstein M, Guillin O, Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006;60:485-95
   PubMed Web of Science ®Google Scholar
• Narendran R, Frankle WG, Mason NS, Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies. Synapse 2009;63:574-84
   PubMedGoogle Scholar
• Rabiner EA, Laruelle M. Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 2010;13:289-90
   PubMedGoogle Scholar
• Rabiner EA, Slifstein M, Nobrega J, In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009;63:782-93
   PubMed Web of Science ®Google Scholar
• Searle G, Beaver JD, Comley RA, Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010;68:392-9
   PubMedGoogle Scholar
• Tziortzi AC, Searle GE, Tzimopoulou S, Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011;54:264-77
   PubMed Web of Science ®Google Scholar
• Day M, Bain E, Marek G, D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol 2010;13:291-2
   PubMedGoogle Scholar
• Graff-Guerrero A, Redden L, Abi-Saab W, Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 2010;13:273-87
   PubMed Web of Science ®Google Scholar
• Heidbreder CA, Newman AH. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 2010;1187:4-34
   PubMed Web of Science ®Google Scholar
• Heidbreder CA, Gardner EL, Xi Z-X, The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 2005;49:77-105
   PubMed Web of Science ®Google Scholar
• Achat-Mendes C, Grundt P, Cao J, Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 2010;334:556-65
   PubMedGoogle Scholar
• Andreoli M, Tessari M, Pilla M, Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003;28:1272-80
   PubMed Web of Science ®Google Scholar
• Gal K, Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull 2003;61:595-601
   PubMedGoogle Scholar
• Higley AE, Kiefer SW, Li X, Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur J Pharmacol 2011;659:187-92
   PubMedGoogle Scholar
• Higley AE, Spiller K, Grundt P, PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol 2011;25:263-73
   PubMedGoogle Scholar
• Micheli F, Bonanomi G, Blaney FE, 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 2007;50:5076-89
   PubMed Web of Science ®Google Scholar
• Orio L, Wee S, Newman AH, The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol 2010;15:312-23
   PubMedGoogle Scholar
• Peng XQ, Ashby CR Jr, Spiller K, The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology 2008;56:752-60
   Google Scholar
• Ross JT, Corrigall WA, Heidbreder CA, Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007;559:173-9
   PubMed Web of Science ®Google Scholar
• Song R, Yang RF, Wu N, YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 2012;17:259-73
   PubMed Web of Science ®Google Scholar
• Vorel SR, Ashby CR Jr, Paul M, Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002;22:9595-603
   PubMed Web of Science ®Google Scholar
• Xi ZX, Gardner EL. Pharmacological actions of NGB-2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 2007;13:240-59
   PubMedGoogle Scholar
• Xi ZX, Gilbert JG, Pak AC, Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost/variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005;21:3427-38
   PubMed Web of Science ®Google Scholar
• Xi ZX, Newman AH, Gilbert JG, The novel dopamine D3 receptor antagonist NGB-2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006;31:1393-405
   PubMed Web of Science ®Google Scholar
• Austin NE, Baldwin SJ, Cutler L, Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001;31:677-86
   PubMed Web of Science ®Google Scholar
• Reavill C, Taylor SG, Wood MD, Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000;294:1154-65
   PubMed Web of Science ®Google Scholar
• Stemp G, Ashmeade T, Branch CL, Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011A): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 2000;43:1878-85
   PubMedGoogle Scholar
• Thanos PK, Katana JM, Ashby CR Jr, The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 2005;81:190-7
   PubMed Web of Science ®Google Scholar
• Millan MJ, Mannoury la Cour C, Novi F, S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 2008;324:587-99
   PubMedGoogle Scholar
• Millan MJ, Svenningsson P, Ashby CR Jr, S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 2008;324:600-11
   PubMed Web of Science ®Google Scholar
• Millan MJ, Loiseau F, Dekeyne A, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008;324:1212-26
   PubMed Web of Science ®Google Scholar
• Rice OV, Patrick J, Schonhar CD, The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge-drinking in C57BL/6J mice. Synapse 2012;66(11):975-8
   PubMedGoogle Scholar
• Pak AC, Ashby CR Jr, Heidbreder CA, The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006;9:585-602
   PubMed Web of Science ®Google Scholar
• Spiller K, Xi ZX, Peng XQ, The selective dopamine D(3) receptor antagonists SB-277011A and NGB-2904 and the putative partial D(3) receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl.) 2008;196:533-42
   PubMed Web of Science ®Google Scholar
• Gilbert J. Proceedings of the 14th Annual Symposium of the International Cannabinoid Research Society (ICRS); 22 – 27 June 2004; Paestum (Italy)
   Google Scholar
• Yuan J, Chen X, Brodbeck R, NGB-2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 1998;8:2715-18
   PubMed Web of Science ®Google Scholar
• Grundt P, Carlson EE, Cao J, Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 2005;48:839-48
   PubMedGoogle Scholar
• Ashby CR Jr, Paul M, Gardner EL, Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003;48:154-6
   PubMed Web of Science ®Google Scholar
• Gyertyan I, Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003;14:93-8
   PubMedGoogle Scholar
• Macdonald GJ, Branch CL, Hadley MS, Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- Phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. J Med Chem 2003;46:4952-64
   PubMed Web of Science ®Google Scholar
• Rice OV, Gardner EL, Heidbreder CA, The acute administration of the selective dopamine D(3) receptor antagonist SB-277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats. Synapse 2012;66:85-7
   PubMedGoogle Scholar
• Swain SN, Beuk J, Heidbreder CA, Beninger RJ. Role of dopamine D(3) receptors in the expression of conditioned fear in rats. Eur J Pharmacol 2008;579:167-76
   PubMed Web of Science ®Google Scholar
• Di Ciano P, Underwood RJ, Hagan JJ, Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003;28:329-38
   PubMed Web of Science ®Google Scholar
• Di Ciano P. Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala. Behav Neurosci 2008;122:129-39
   PubMed Web of Science ®Google Scholar
• Cervo L, Cocco A, Petrella C, Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007;10:167-81
   PubMed Web of Science ®Google Scholar
• Gal K, Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 2006;81:63-70
   PubMedGoogle Scholar
• Gilbert JG, Newman AH, Gardner EL, Acute administration of SB-277011A, NGB-2904, or BP-897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005;57:17-28
   PubMed Web of Science ®Google Scholar
• Campiani G, Butini S, Trotta F, Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003;46:3822-39
   PubMed Web of Science ®Google Scholar
• Khaled MA, Farid Araki K, Li B, The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP-897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol 2010;13:181-90
   PubMed Web of Science ®Google Scholar
• Heidbreder CA, Andreoli M, Marcon C, Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007;12:35-50
   PubMed Web of Science ®Google Scholar
• Epstein DH, Preston KL, Stewart J, Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl.) 2006;189:1-16
   PubMed Web of Science ®Google Scholar
• Xi ZX, Gilbert J, Campos AC, Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl.) 2004;176:57-65
   PubMed Web of Science ®Google Scholar
• Mugnaini M, Iavarone L, Cavallini P, Occupancy of brain dopamine D(3) receptors and drug craving: a translational approach. Neuropsychopharmacol 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004;28:771-84
   PubMed Web of Science ®Google Scholar
• Sato K, Ueda H, Okumura F, 6-OHDA-induced lesion of the nigrostriatal dopaminergic neurons potentiates the inhibitory effect of 7-OHDPAT, a selective D3 agonist, on acetylcholine release during striatal microdialysis in conscious rats. Brain Res 1994;655:233-6
   PubMedGoogle Scholar
• Sigala S, Missale C, Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol 1997;336:107-12
   PubMed Web of Science ®Google Scholar
• Lacroix LP, Hows ME, Shah AJ, Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003;28:839-49
   PubMed Web of Science ®Google Scholar
• Lacroix LP, Ceolin L, Zocchi A, Selective dopamine D(3) receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 2006;157:25-31
   PubMed Web of Science ®Google Scholar
• Millan MJ, Di Cara B, Dekeyne A, Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007;100:1047-61
   PubMed Web of Science ®Google Scholar
• Laszy J, Laszlovszky I, Gyertyan I. Dopamine D3 receptor antagonists improve the learning performance of memory-impaired rats. Psychopharmacology (Berl.) 2005;179:567-75
   PubMed Web of Science ®Google Scholar
• Millan MJ, Buccafusco JJ, Loiseau F, The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 2010;13:1035-51
   PubMed Web of Science ®Google Scholar
• Watson DJ, Loiseau F, Ingallinesi M, Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 2012;37:770-86
   PubMedGoogle Scholar
• Loiseau F, Millan MJ. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur Neuropsychopharmacol 2009;19:23-33
   PubMedGoogle Scholar
• Watson DJ, Marsden CA, Millan MJ, Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 2012;15:471-84
   PubMedGoogle Scholar
• Glickstein SB, Desteno DA, Hof PR, Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2005;15:1016-24
   PubMed Web of Science ®Google Scholar
• Micale V, Cristino L, Tamburella A, Enhanced cognitive performance of dopamine D3 receptor “knock-out” mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res 2010;61:531-6
   PubMed Web of Science ®Google Scholar
• Xing B, Meng X, Wei S, Influence of dopamine D3 receptor knockout on age-related decline of spatial memory. Neurosci Lett 2010;481:149-53
   PubMedGoogle Scholar
• Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 1999;128:78-87
   PubMed Web of Science ®Google Scholar
• Moeller FG, Dougherty DM, Barratt ES, Increased impulsivity in cocaine dependent subjects independent of antisocial personality disorder and aggression. Drug Alcohol Depend 2002;68:105-11
   PubMed Web of Science ®Google Scholar
• Petry NM. Substance abuse, pathological gambling, and impulsiveness. Drug Alcohol Depend 2001;63:29-38
   PubMed Web of Science ®Google Scholar
• Vuchinich RE, Simpson CA. Hyperbolic temporal discounting in social drinkers and problem drinkers. Exp Clin Psychopharmacol 1998;6:292-305
   PubMed Web of Science ®Google Scholar
• Madden GJ, Petry NM, Badger GJ, Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards. Exp Clin Psychopharmacol 1997;5:256-62
   PubMed Web of Science ®Google Scholar
• Leyton M, Boileau I, Benkelfat C, Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002;27:1027-35
   PubMed Web of Science ®Google Scholar
• Thome J, Weijers HG, Wiesbeck GA, Dopamine D3 receptor gene polymorphism and alcohol dependence: relation to personality rating. Psychiatr Genet 1999;9:17-21
   PubMed Web of Science ®Google Scholar
• Meszaros K, Lenzinger E, Hornik K, The Tridimensional Personality Questionnaire as a predictor of relapse in detoxified alcohol dependents. The European Fluvoxamine in Alcoholism Study Group. Alcohol Clin Exp Res 1999;23:483-6
   PubMed Web of Science ®Google Scholar
• Boileau I, Assaad JM, Pihl RO, Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003;49:226-31
   PubMed Web of Science ®Google Scholar
• Vandenbergh DJ, O'Connor RJ, Grant MD, Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addict Biol 2007;12:106-16
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Bordelon Y, Shapiro RM, Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997;54:225-32
   PubMed Web of Science ®Google Scholar
• Schwartz JC, Diaz J, Pilon C, Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000;31:277-87
   PubMed Web of Science ®Google Scholar
• Mogenson GJ, Yang CR, Yim CY. Influence of dopamine on limbic inputs to the nucleus accumbens. Ann NY Acad Sci 1988;537:86-100
   PubMed Web of Science ®Google Scholar
• Meincke U, Morth D, Voss T, Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis-a longitudinal study. Eur Arch Psychiatry Clin Neurosci 2004;254:415-21
   PubMed Web of Science ®Google Scholar
• Zhang M, Ballard ME, Unger LV, Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res 2007;182:1-11
   PubMed Web of Science ®Google Scholar
• Zhang M, Ballard ME, Kohlhaas KL, Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006;31:1382-92
   PubMed Web of Science ®Google Scholar
• Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-19
   PubMed Web of Science ®Google Scholar
• Southam E, Lloyd A, Jennings CA, Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain. Brain Res 2007;1149:50-7
   PubMed Web of Science ®Google Scholar
• Robertson GS, Lee CJ, Sridhar K, Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004;20:3189-94
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27
   PubMed Web of Science ®Google Scholar
• Guillin O, Diaz J, Carroll P, BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86-9
   PubMed Web of Science ®Google Scholar
• Dawson NM, Hamid EH, Egan MF, Changes In the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001;39:70-81
   PubMed Web of Science ®Google Scholar
• Dubertret C, Gorwood P, Ades J, Meta-analysis of Drd3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 1998;81:318-22
   PubMed Web of Science ®Google Scholar
• Jonsson EG, Flyckt L, Burgert E, Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 2003;13:1-12
   PubMed Web of Science ®Google Scholar
• Serretti A, Lattuada E, Cusin C, Dopamine D3 receptor-gene-not-associated-with-symptomatology-of-major-psychoses. Am J Med Genet 1999;88:476-80
   PubMed Web of Science ®Google Scholar
• Krebs MO, Sautel F, Bourdel MC, Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 1998;3:337-41
   PubMed Web of Science ®Google Scholar
• Ebstein RP, Macciardi F, Heresco-Levi U, Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47:6-16
   PubMed Web of Science ®Google Scholar
• Griffon N, Crocq MA, Pilon C, Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996;67:63-70
   PubMed Web of Science ®Google Scholar
• Nimgaonkar VL, Sanders AR, Ganguli R, Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. Am J Med Genet 1996;67:505-14
   PubMed Web of Science ®Google Scholar
• Lerer B, Segman RH, Fangerau H, Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-19
   PubMed Web of Science ®Google Scholar
• Gourion D, Goldberger C, Leroy S, Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. Neuroreport 2005;16:1407-10
   PubMed Web of Science ®Google Scholar
• Bezard E, Ferry S, Mach U, Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-7
   PubMed Web of Science ®Google Scholar
• Silverdale MA, Nicholson SL, Ravenscroft P, Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004;188:128-38
   PubMed Web of Science ®Google Scholar
• O'Connell DP, Vaughan CJ, Aherne AM, Expression of the dopamine D3 receptor protein in the rat kidney. Hypertension 1998;32:886-95
   PubMed Web of Science ®Google Scholar
• Luippold G, Beilharz M, Wehrmann M, Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2005;371:420-7
   PubMed Web of Science ®Google Scholar
• Gross ML, Koch A, Muhlbauer B, Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab Invest 2006;86:262-74
   PubMed Web of Science ®Google Scholar
• Kitrey ND, Clement P, Bernabe J, Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience 2007;149:636-41
   PubMed Web of Science ®Google Scholar
• Clement P, Bernabe J, Denys P, Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats. Neuroscience 2007;145:605-10
   PubMed Web of Science ®Google Scholar
• Clement P, Pozzato C, Heidbreder C, Delay of ejaculation induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. J Sex Med 2009;6:980-8
   PubMed Web of Science ®Google Scholar
• Gyertyan I, Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007;572:171-4
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Newman-Tancredi A, S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1048-62
   PubMed Web of Science ®Google Scholar
• Millan MJ, Dekeyne A, Rivet JM, S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1063-73
   PubMed Web of Science ®Google Scholar
• Siuciak JA, Fujiwara RA. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl.) 2004;175:163-9
   PubMed Web of Science ®Google Scholar
• Chourbaji S, Brandwein C, Vogt MA, Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res 2008;58:302-7
   PubMedGoogle Scholar
• Martelle JL, Claytor R, Ross JT, Effects of two novel D3-selective compounds, NGB-2904 [N-(4-(4-(2,3 dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 2007;321:573-82
   PubMed Web of Science ®Google Scholar
• Thanos PK, Michaelides M, Ho CW, The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav 2008;89:499-507
   PubMedGoogle Scholar
• Nathan PJ, O'Neill BV, Mogg K, The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 2012;15:149-61
   PubMedGoogle Scholar
• Mogg K, Bradley BP, O'Neill B, Effect of dopamine D(3) receptor antagonism on approach responses to food cues in overweight and obese individuals. Behav Pharmacol 2012;23:603-8
   PubMed Web of Science ®Google Scholar
• Dodds CM, O'Neill B, Beaver J, Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 2012;27-33
   PubMedGoogle Scholar
• Bocker A, Sasse BC, Nietert M, GPCR targeted library design: novel dopamine D3 receptor ligands. ChemMedChem 2007;2:1000-5
   PubMedGoogle Scholar
• Pilla M, Perachon S, Sautel F, Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999;400:371-5
   PubMed Web of Science ®Google Scholar
• Hackling A, Ghosh R, Perachon S, N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem 2003;46:3883-99
   PubMedGoogle Scholar